NT5C2
NT5C2 (Cytosolic purine 5'-nucleotidase) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Non-Hodgkin lymphoma, Breast cancer and 1 more.
Overview
Broad specificity cytosolic 5'-nucleotidase that catalyses the dephosphorylation of 6-hydroxypurine nucleoside 5'-monophosphates. In addition, possesses a phosphotransferase activity by which it can transfer a phosphate from a donor nucleoside monophosphate to an acceptor nucleoside, preferably inosine, deoxyinosine and guanosine. Has the highest activities for IMP and GMP followed by dIMP, dGMP and XMP.
CIViC holds 18 clinical evidence items and 0 assertions across 6 variants, naming Mercaptopurine, Thioguanine, Nelarabine and Arabinosylguanine and others. Open Targets scores its association with cancer at 0.61 (direct and indirect evidence; datatypes literature 0.75, genetic association 0.00, somatic mutation 0.97).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · NT5C2 (Cytosolic purine 5'-nucleotidase) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Non-Hodgkin lymphoma, Breast cancer and 1 more.
- 1 · What it is
NT5C2 (Cytosolic purine 5'-nucleotidase) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Non-Hodgkin lymphoma, Breast cancer and 1 more.
- 2 · What goes wrong in cancer
Broad specificity cytosolic 5'-nucleotidase that catalyses the dephosphorylation of 6-hydroxypurine nucleoside 5'-monophosphates.
- 3 · How drugs use it
No product in this corpus aims at NT5C2 yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
External identifiers
Sources: HGNC HGNC:8022 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P49902 (protein name, function text, keywords and locations (REST API)); CIViC gene NT5C2 (18 evidence items, 0 assertions, 6 variants; diseases: Childhood Acute Lymphocytic Leukaemia, T-cell Acute Lymphoblastic Leukaemia, Acute Lymphoblastic Leukaemia, B-lymphoblastic Leukaemia/lymphoma (GraphQL API, CC0)); Open Targets ENSG00000076685 (association with cancer (MONDO_0004992) 0.61; per-cancer scores at or above 0.5: acute lymphoblastic leukaemia 0.53, non-Hodgkin lymphoma 0.55, breast cancer 0.50, leukaemia 0.55 (GraphQL API, CC0))
Biology
Broad specificity cytosolic 5'-nucleotidase that catalyses the dephosphorylation of 6-hydroxypurine nucleoside 5'-monophosphates. In addition, possesses a phosphotransferase activity by which it can transfer a phosphate from a donor nucleoside monophosphate to an acceptor nucleoside, preferably inosine, deoxyinosine and guanosine. Has the highest activities for IMP and GMP followed by dIMP, dGMP and XMP. Could also catalyse the transfer of phosphates from pyrimidine monophosphates but with lower efficiency. Through these activities regulates the purine nucleoside/nucleotide pools within the cell. Location: Cytoplasm, cytosol (UniProt). Locus 10q24.32-q24.33 (HGNC).
- Leukaemia: Open Targets association 0.55 with leukaemia (MONDO_0005059)
- Non-Hodgkin lymphoma: Open Targets association 0.55 with non-Hodgkin lymphoma (MONDO_0018908)
- Breast cancer: Open Targets association 0.50 with breast cancer (MONDO_0007254)
- Acute lymphoblastic leukaemia: Open Targets association 0.53 with acute lymphoblastic leukaemia (MONDO_0004967); CIViC evidence names this disease
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 8 therapies; CIViC holds 18 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
- Diseases the sources name that have no OnCo cancer page yet, so they are not linked: Childhood Acute Lymphocytic Leukaemia; T-cell Acute Lymphoblastic Leukaemia.
Latest papers
topQuery for this target: (TITLE:"NT5C2" OR ABSTRACT:"NT5C2" OR TITLE:"5'-nucleotidase, cytosolic II" OR ABSTRACT:"5'-nucleotidase, cytosolic II" OR TITLE:"Cytosolic purine 5'-nucleotidase" OR ABSTRACT:"Cytosolic purine 5'-nucleotidase" OR TITLE:"PNT5" OR ABSTRACT:"PNT5" OR TITLE:"cN-II" OR ABSTRACT:"cN-II" OR TITLE:"SPG65" OR ABSTRACT:"SPG65") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about NT5C2, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetGATA3
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia, Breast cancer (all types).
- TargetMLLT10
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia, Breast cancer (all types).
- TargetARID5B
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia, Open Targets Platform.
- TargetBAK1
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia, Open Targets Platform.
- TargetCEP43
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia, Open Targets Platform.
- TargetGNB1
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia, Open Targets Platform.
- TargetPPAT
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia, Open Targets Platform.
- TargetSET
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia, Open Targets Platform.